Previous Abstract | Next Abstract
Printable Version
YI02-4
October 14, 2018
10/14/2018 10:00:00 AM - 10/14/2018 11:30:00 AM
Room North, Room 22
Metabolomic Impact of Lidocaine on Breast Cancer Cell Lines
Thien-Nga Chamaraux-Tran, M.D., Nassim Dali-Youcef, M.D., Elisa Ruhland, M.Eng., Girish P. Joshi, M.D., Catherine Tomasetto, Ph.D., Eric Noll, M.D.,Ph.D., Izzie-Jacques Namer, M.D.,Ph.D., Pierre A. Diemunsch, M.D.,Ph.D.
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Disclosures: T. Chamaraux-Tran: Funded Research; Self; IGBMC International Ph.D. Program fellow supported by LabEx INRT funds (grant ANR-10-LABX-0030-INRT), Société Française d'anesthésie-réanimation. N. Dali-Youcef: None. E. Ruhland: None. G.P. Joshi: Consulting Fees; Self; Pacira, Baxter, Mallincrodt and Merck Pharmaceuticals. C. Tomasetto: None. E. Noll: None. I. Namer: None. P.A. Diemunsch: None.
Background: Metabolomics and oncoanesthesia are 2 emerging research fields in oncology. Metabolomics (metabolites analysis) is a new diagnostic and prognostic tool that can be also used for predicting therapeutic or toxicity responses of anticancer treatments (1). Oncoanesthesia studies assess the impact of anesthesia on disease-free and overall survival after cancer surgery. It has been shown that local anesthetics (LA), particularly lidocaine (LIDO), exerts in vitro and in vivo antitumor properties (2). As LA are known to impair mitochondrial bioenergism (3), the aim of the present study was to assess the impact of LIDO on metabolomic profile of a breast cancer cell line.

Methods:
107 breast cancer MDA-MB-231 cells were exposed for 4 h to 500 μM LIDO or vehicle (n=4). The metabolomic fingerprint was characterized by high resolution magic angle spinning NMR spectroscopy (HRMAS). The multivariate technique using the Algorithm to Determine Expected Metabolite Level Alteration (ADEMA) based on mutual information to identify expected metabolite level changes with respect to a specific condition was used to determine the metabolites variations caused by LIDO.

Results:
Metabolites modulation is represented in figure 1. Several pathways: glutaminolysis, choline, phosphocholine and total choline syntheses were statically significantly downregulated in LIDO group.

Discussion:
This is the first study assessing the impact of LIDO on metabolomic fingerprint of breast cancer cells. High levels of metabolites of the pathways downregulated by LIDO are reported to be associated with adverse prognosis. These results fit with the antitumor properties of LIDO and suggest its impact on metabolomics profile of cancer cells. These effects of LIDO are of clinical significance because it is widely used for cutaneous infiltration during percutaneous tumor biopsy. Future in vitro and preclinical studies are necessary to assess if metabolomics requires modification of local anesthetic techniques during tumor biopsy.

REFERENCES: 1. Beger RD. A Review of Applications of Metabolomics in Cancer. Metabolites. 2013 Jul 5;3(3):552-74. 2. Chamaraux-Tran T-N, Mathelin C, Aprahamian M, Joshi GP, Tomasetto C, Diemunsch P, et al. Antitumor Effects of Lidocaine on Human Breast Cancer Cells: AnIn VitroandIn VivoExperimental Trial. Anticancer Res. 2018;38(1):95-105. 3. Nouette-Gaulain K, Jose C, Capdevila X, Rossignol R. From analgesia to myopathy: When local anesthetics impair the mitochondrion. Int J Biochem Cell Biol. 2011 Jan 1;43(1):14-9.

This study was supported by the grant ANR-10-LABX-0030-INRT, a French State fund managed by the Agence Nationale de la Recherche under the frame program Investissements d’Avenir ANR-10-IDEX-0002-02.”
T-N. C-T is an IGBMC International PhD Programme fellow supported by LabEx INRT funds and has also received grants from the SFAR (French Society of Anesthesia & Intensive Care Medicine).
Figure 1

Copyright © 2018 American Society of Anesthesiologists